All In Biotech

Drug Trial Radar · NCT00114777

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)

Last checked: Nov 20, 2026Latest source record: Jul 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 595 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

595

Actual

Start

Feb 2005

Primary completion

May 2008

Study completion Sep 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.

Conditions

  • Renal Transplantation

Interventions

  • Cyclosporin ADrug

    tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months

  • Belatacept Less Intensive Regimen (LI)Drug

    solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months

  • Belatacept More Intensive Regimen (MI)Drug

    solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Survived With a Graft at 12 Months Post-TransplantTime frame: Month 12 post-transplant
  2. Percentage of Participants With a Measured Glomerular Filtration Rate (GFR) <60 mL/Min Per 1.73 m^2 at Month 12 or a Decrease in Measured GFR >=10 mL/Min Per 1.73 m^2 From Month 3 to Month 12Time frame: From Month 3 to Month 12

Locations

79 sites in 19 countries. Site status is shown where the registry gives one.

  • University Of Alabama At Birmingham

    Birmingham, Alabama

  • Ucla Kidney & Kidney-Pancreas Transplant Research Office

    Los Angeles, California

  • National Institute Of Transplantation

    Los Angeles, California

  • Sharp Memorial Hospital

    San Diego, California

  • University Of California San Francisco Medical Center

    San Francisco, California

  • University Of Colorado Health Sciences Center

    Aurora, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Lifelink Healthcare Institute

    Tampa, Florida

  • Piedmont Transplant Institute

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern University-Feinberg School Of Medicine

    Chicago, Illinois

  • University Of Chicago Hospitals

    Chicago, Illinois

  • Acadiana Renal Physicians

    New Iberia, Louisiana

  • Tulane Abdominal Transplant Institute

    New Orleans, Louisiana

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Western New England Renal & Transplant Associates, Pc

    Springfield, Massachusetts

  • Henry Ford Hospital, Transplant Institute

    Detroit, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • Mount Sinai School Of Medicine

    New York, New York

  • Columbia University College Of Physicians & Surgeons

    New York, New York

  • University Of North Carolina At Chapel Hill

    Chapel Hill, North Carolina

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Drexel University College Of Medicine, Department Of Surgery

    Philadelphia, Pennsylvania

  • University Of Pennsylvania

    Philadelphia, Pennsylvania

  • Baylor University Medical Center

    Dallas, Texas

  • University Of Wisconsin

    Madison, Wisconsin

  • Froedtert Memorial Hospital

    Milwaukee, Wisconsin

  • Local Institution

    Santa Fe, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Cordoba, Crd, Córdoba Province, Argentina

  • Local Institution

    Rosario, Santa Fe Province, Argentina

  • Local Institution

    Woodville, South Australia, Australia

  • Local Institution

    Innsbuck, Austria

  • Local Institution

    Vienna, Austria

  • Local Institution

    Leuven, Belgium

  • Local Institution

    Rio de Janeiro, Brazil

  • Local Institution

    São Paulo, Brazil

  • Local Institution

    São Paulo, Brazil

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.